With delicious aromas wafting from the kitchen and holiday cheer all around, there’s nothing better than spending Thanksgiving at home among loved ones. However, if you’re stranded at an airport or stuck in traffic on your way home, it’s easy to become a Thanksgiving Grinch.
Fortunately, even if you’re far from hearth and home, the performance of the Dow, Nasdaq, and The S&P 500 this year gives you plenty to be thankful for – particularly if you’re holding any of 2014’s best performing stocks. Below, you’ll find a list of seven high performing stocks to be thankful for this year:
Radnet, Inc. (RDNT)
This outpatient diagnostic imaging service is up an incredible 420.96% this year after signing a number of new clients this year. Radnet’s centers provide physicians with imaging capabilities to facilitate the diagnosis and treatment of diseases and disorders, but if you’ve been holding their stock all year, your portfolio should be very healthy indeed.
Avanir Pharmaceuticals, Inc. (AVNR)
A pharmaceutical company that’s focused on developing and commercializing therapeutic products for the treatments of central nervous system disorders. Avanir Pharmaceuticals is up 330.36% over the course of the year thus far, and the markets expect an improvement in earnings (-$0.30 compared to -$0.53) this year.
Receptos, Inc. (RCPT)
A biopharmaceutical company that is providing stockholders with a jolly holiday this year, thanks to their 328.24% increase in value this year. What’s more, their stock has surged 20.61% for the week going into Thanksgiving, so if you’re holding onto Receptos, feel free to spring for the jumbo-size turkey for the holiday.
Pernix Therapeutics Holdings, Inc. (PTX)
Yet another specialty pharmaceutical company that develops, markets and sells branded and generic pharmaceutical products. While Pernix Therapeutics earnings per share are at -$0.75 – below the sector average of -0.11 – the stock is still up 321.43% over the year, providing plenty of comfort and joy this holiday season for stockholders who got on board last January.
Agios Pharmaceuticals, Inc. (AGIO)
You guessed it, another biopharmaceutical company that has seen a very strong year, with an increase in value of 309.31% this year. Agios Pharmaceuticals utilizes a fundamental understanding of metabolism to create medicines that can inhibit or activate metabolic enzymes that change the way cancer and inborn errors in metabolism are treated. As a holder of exclusive U.S. development and commercial rights to AG-120, a first-in-class oncology therapy that has shown clinical activity and human safety against hematologic malignancies, making the prospects seem very bright for Agios Pharmaceuticals stockholders long after the leftovers have gone cold.
Prosensa Holding N.V. (RNA)
A biotech company involved in the discovery and development of (RNA)-modulating, therapeutics for the treatment of genetic disorders. Like many companies in this field, Prosensa Holding N.V. has seen a very strong year, with stock up 300.43%. This is largely thanks to a surge of 62.61% this week after BioMarin Pharmaceutical (BMRN) agreed to purchase the company – a stunning stock increase, just in time for the holidays.
Achillion Pharmaceuticals, Inc. (ACHN)
Achillion is a biopharmaceutical company focused on the discovery, development and commercialization of treatments for infectious diseases. In October, Achillion presented four abstracts at the American Association for the Study of Liver Diseases that showed good safety and tolerability for Hepatitis C patients, leading to gains of 18%, boosting the yearly stock increase for the company to 284.19%. Though the company is still a little ways off from bringing a drug to market, the gains made this year are still more than enough to warrant an extra slice of pumpkin pie for those who purchased stock prior to October.
DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer